122 studies found for:    Open Studies | niaid
Show Display Options
Rank Status Study
21 Recruiting CLAD Phenotype Specific Risk Factors and Mechanisms.
Condition: Lung Transplant
Interventions: Procedure: Blood Draw;   Procedure: Bronchoscopy
22 Recruiting Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Conditions: Healthy;   Rheumatoid Arthritis Prevention
Interventions: Drug: Hydroxychloroquine;   Drug: HCQ Placebo
23 Recruiting Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: D46cpΔM2-2 vaccine;   Biological: Placebo
24 Not yet recruiting Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01;   Drug: Antiretroviral therapy (ART) (regimen will vary within countries and by patient)
25 Not yet recruiting Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis
Conditions: Tuberculosis;   HIV Infections
Interventions: Drug: Bedaquiline;   Drug: Delamanid;   Drug: Dolutegravir
26 Recruiting Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Condition: Influenza A Virus Infection
Interventions: Biological: High-titer anti-influenza plasma;   Biological: Low-titer (control) anti-influenza plasma
27 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
28 Recruiting Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
Conditions: Liver Transplant;   Liver Transplantation
Intervention: Procedure: Immunosuppression withdrawal
29 Recruiting Integrase and Maraviroc Intensification for Neurocognitive Dysfunction (InMIND)
Condition: HIV Infections
Interventions: Drug: Placebo for maraviroc (MVC);   Drug: Placebo for dolutegravir (DTG);   Drug: Dolutegravir (DTG);   Drug: Maraviroc (MVC)
30 Recruiting Registry for Asthma Characterization and Recruitment 2
Condition: Asthma
Intervention:
31 Recruiting Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
Condition: Asthma
Intervention:
32 Recruiting Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Condition: Kidney Transplant
Interventions: Biological: Infliximab;   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Biological: Thymoglobulin;   Drug: Acetaminophen;   Drug: Loratadine;   Biological: Placebo for Infliximab;   Drug: Prednisone;   Drug: Diphenhydramine
33 Recruiting Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Condition: HIV Infections
Intervention: Drug: Ruxolitinib
34 Recruiting Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
Conditions: Liver Transplant Recipient;   Living Donor (of the Respective Liver Transplant Recipient)
Interventions: Biological: darTregs;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Immunosuppression (IS) Withdrawal;   Procedure: Study Mandated Procedures
35 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Condition: Dengue
Interventions: Biological: Recombinant live attenuated trivalent dengue vaccine;   Biological: Placebo;   Biological: rDEN2Δ30-7169 vaccine
36 Recruiting Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX®-GP HIV-1 DNA vaccine;   Biological: Interleukin-12 (IL-12) DNA adjuvant;   Biological: Placebo
37 Recruiting Autologous Polyclonal Tregs for Lupus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic
Intervention: Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
38 Recruiting Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Condition: Dengue
Interventions: Biological: rDEN1Δ30;   Biological: Placebo;   Biological: rDEN2Δ30-7169
39 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
40 Recruiting Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
Condition: Dengue
Interventions: Biological: TV003;   Biological: Placebo for TV003

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years